The genomic urine testing market will be worth USD 137.0 million in 2025. The market will acquire a total valuation of USD 293.6 million by 2035, reflecting a CAGR of 7.9% throughout the forecast period between 2025 and 2035.
In 2024, the genomic urine testing market made tremendous breakthroughs through tech innovations and a growing focus on non-invasive diagnostic approaches. One of the developments included the launch of at-home digital urinary tract infection (UTI) tests by firms such as Vivoo.
It introduced a test in January 2024 that allows one to do a urine test within two minutes, and the results are made available immediately through a smartphone application. This innovation obviated the necessity for visits to laboratories, providing greater convenience and responding to the increasing consumer demand for personalized, point-of-care diagnostics.
The industry also experienced an increase in the use of genomic urine testing for cancer early detection and monitoring.
The industry for genomic urine testing is expected to continue growing throughout the forecast period between 2025 and 2035. Some major drivers are continuous technological developments, including innovations in next-generation sequencing (NGS) and polymerase chain reaction (PCR) technologies, which improve test accuracy and scalability. Also, the increasing use of genomic urine testing outside oncology for cardiovascular disorders, genetic diseases, infectious diseases, and neurological disorders is likely to continue driving industry growth.
Despite this, challenges still exist in the form of the need for advanced data analysis programs with which to decipher complex genomic data and standardization across labs to provide consistent and reliable results.
| Metrics | Values |
|---|---|
| Industry Size (2025E) | USD 137.0 million |
| Industry Value (2035F) | USD 293.6 million |
| CAGR | 7.9% |
Explore FMI!
Book a free demo
The genomic urine testing market is on a steady growth path. It is driven by increasing demand for non-invasive, early diagnosis technologies in oncology and chronic disease management. Advances in genomic sequencing and mobile health platforms are driving adoption and use cases. Diagnostic firms and digital health disruptors will gain the most, while traditional lab-based testing firms will lose ground if they fail to adapt.
Invest in At-Home Diagnostic Platforms
Leverage the consumer move toward convenience through the development or acquisition of easy-to-use, smartphone-enabled genomic urine tests. Focus on ease of UX, fast turnaround, and remote physician connectivity to acquire a competitive advantage.
Align with Precision Medicine and Early Detection Trends
Enhance product functionality to accommodate early-stage diagnosis and tailored treatment planning, particularly in oncology and the management of chronic diseases. Make sure to be interoperable with genomic information platforms and electronic medical records in order to keep up with healthcare ecosystem development.
Establish Strategic Alliances and Increase R&D Presence
Align with biotech companies, digital health companies, and research institutions to drive innovation and verification. Ponder strategic M&A to in-license IP, add test menus, or secure industry access in important geographies.
| Risk | Probability - Impact |
|---|---|
| Regulatory Delays or Reclassifications | Medium - High |
| Data Privacy and Security Breaches | High - High |
| Technological Obsolescence or Platform Incompatibility | Medium - Medium |
| Priority | Immediate Action |
|---|---|
| At-Home Test Commercialization | Run feasibility study on direct-to-consumer genomic urine test rollout . |
| Clinical Integration Expansion | Initiate a feedback loop with health systems on genomic test adoption barriers . |
| Channel & Distribution Strategy | Launch pilot incentive program for digital health and telehealth partners |
To remain ahead, the roadmap now has to incorporate accelerated product iteration cycles, regulatory interaction strategies, and a systematic process of entering new clinical verticals like oncology and nephrology. The executives should consider this moment as not only a growth opportunity but also as an opportunity to rethink the company's positioning in the future of precision diagnostics.
(Surveyed Q4 2024, n=475 stakeholder participants evenly distributed across diagnostic companies, hospital networks, digital health firms, and lab technicians in the US, Western Europe, Japan, and South Korea)
Regional Variance:
ROI Perspective:
Consensus:
Variance:
Diagnostic Providers:
Digital Health Players:
Lab Technicians:
Alignment:
Regional Focus:
High Consensus:
Key Divergences:
Strategic Insight:
| Countries | Regulatory Impact and Mandatory Certifications |
|---|---|
| United States |
|
| European Union (EU) |
|
| Germany |
|
| France |
|
| Japan |
|
| South Korea |
|
The USA industry for genomic urine testing is steadily growing, fueled by the progress made in personalized medicine and a strong focus on non-invasive diagnostic technologies. The inclusion of genomic information in standard clinical practices has been eased through favorable regulatory environments and heavy investment in healthcare technology. The fact that the industry is supported by top biotech companies and research centers also helps fuel innovation and adoption. Data privacy issues and the requirement for standardized protocols remain some of the issues holding back the industry.
FMI projects that USA genomic urine testing sales are likely to expand at a CAGR of 4.9% between 2025 to 2035
India's industry for genomic urine testing is in its infancy but has high potential based on a vast population base and rising awareness for genetic disorders. Healthcare infrastructure growth and the government's efforts towards biotechnology research drive growth. The developing prevalence of chronic diseases coupled with an expanding middle class ready to spend on sophisticated diagnostics drive industry growth. However, the difficulties involve restricted access to high-tech healthcare facilities in rural regions and a lack of professional expertise.
FMI forecasts that India's genomic urine testing sales will grow at a CAGR of approximately 7.5% from 2025 to 2035.
China's genomic urine testing industry is growing quickly, fueled by huge investments in biotechnology and government emphasis on precision medicine. The nation's vast population and rising prevalence of chronic diseases create a need for sophisticated diagnostic technologies. Partnerships between local and foreign firms are boosting technological prowess. Regulatory changes to speed up the approval process for new medical technologies further aid industry growth.
FMI projects that China's genomic urine testing sales will grow a CAGR of 8.5% by 2035.
The UK genomic urine testing industry is supported by a strong healthcare system and programs such as the 100,000 Genomes Project, which embed genomics in everyday care. Strong partnerships between the National Health Service (NHS), academia, and private industry fuel innovation.
Public understanding and acceptance of genetic testing are fairly high, making adoption easier. Challenges, however, include dealing with complicated regulatory environments after Brexit and maintaining data privacy compliance.
FMI projects that U.K. genomic urine testing sales are likely to expand at a CAGR of 5.0% between 2025 to 2035
Germany's genomic urine testing industry is dominated by a high focus on research and development, backed by a well-developed healthcare infrastructure. The nation's interest in precision medicine and personalized healthcare creates demand for sophisticated diagnostic equipment.
University, research institute, and biotech firm collaborations drive innovation. Stringent regulatory standards and the necessity for extensive clinical validation can be challenging to industry entry, though.
FMI projects that Germany genomic urine testing sales are likely to expand at a CAGR of 6.5% between 2025 to 2035
South Korea's industry for genomic urine testing is expanding with the support of government policies favoring biotechnology and precision medicine. The high-tech healthcare infrastructure and high level of new technology adoption in the country make industry penetration easier. There are frequent collaborations between research institutions and biotech companies, which improve research and development capabilities. Challenges lie in overcoming regulatory approvals and responding to ethical concerns over genetic testing.
FMI projects that South Korea genomic urine testing sales are likely to expand at a CAGR of 7.9% between 2025 to 2035
Japan's industry for genomic urine testing is growing because of an aging populace and a high emphasis on early detection of disease. Public policies favoring genomic investigation and individualized medicine programs drive industry development. Foreign collaborations with research centers accelerate technological development. Cultural sentiments for genetic testing and data confidentiality concerns might influence levels of adoption.
FMI projects that Japan genomic urine testing sales are likely to expand at a CAGR of 8.2% between 2025 to 2035
France's genomic urine testing industry is supported by robust government backing for genomic studies and incorporation in healthcare. Projects such as the French Plan for Genomic Medicine 2025 set out to make the nation a hub of personalized medicine. Public coverage of genetic tests increases availability. Bureaucratic procedures and regulatory hurdles, nonetheless, may hamper the adoption of new technology.
FMI projects that France's genomic urine testing sales are likely to expand at a CAGR of 5.5% between 2025 to 2035
Italy's genomic urine testing industry is emerging, driven by growing awareness of personalized medicine and government efforts to update healthcare services. University-biotech collaborations are driving innovation. Economic limitations and regional differences in healthcare infrastructure could slow adoption.
FMI projects that Italy genomic urine testing sales are likely to expand at a CAGR of 5.0% between 2025 to 2035
The Australian and New Zealand industry for genomic urine testing is expanding due to developed healthcare systems and robust research environments. Government initiatives toward genomic research funding and prioritization of personalized medicine drive the growth of the industry.
Increased public awareness and acceptability of genetic testing aid in adoption. Nonetheless, ensuring fair access to remote locations and dealing with regulatory harmonization across the two nations remain challenges.
FMI projects that Australia-NZ genomic urine testing sales are likely to expand at a CAGR of 6.0% between 2025 to 2035
Between 2025 and 2035, Bladder Cancer Surveillance will be the most profitable application segment in the genomic urine testing industry. This is mainly fueled by the rising global incidence of bladder cancer, which requires non-invasive and reproducible testing techniques for monitoring the disease over the long term.
In contrast to primary detection, which may be a single or occasional occurrence, bladder cancer surveillance involves continuous testing over a period of months or years, and so presents itself as a recurring revenue stream for diagnostic companies.
Clinical guidelines are also increasingly incorporating genomic urine assays for post-treatment surveillance to minimize the use of invasive procedures such as cystoscopy. Health systems are willing to embrace these methods based on better patient compliance, diminished procedural risk, and long-term cost savings.
With the help of increased sensitivity of genomic assays and wider awareness among physicians, the Bladder Cancer Surveillance industry is expected to register a CAGR of about 8.9% from 2025 through 2035, higher than the industry CAGR of 7.9%.
Between 2025 and 2035, Mail Order Pharmacies will be the highest-paying distribution channel for genomic urine testing, driven by their scalability, ease of use, and fit with digital health trends. With great momentum expected for remote diagnostic models-particularly after COVID-mail-order systems are facilitating effortless sample logistics between patients and laboratories without the necessity of an office visit.
This model is particularly beneficial for genomic urine tests, as they are non-invasive and self-collectable. In addition, collaborations between mail-order services and diagnostic firms are shortening test turnaround times and improving access in rural or underserved communities. Regulators in a number of countries also promote decentralized testing channels for easing hospital burden.
All things considered, Mail Order Pharmacies are predicted to develop at a CAGR of around 8.5% from 2025 to 2035, surpassing other channels in the expansion of volume and margin.
The genomic urine testing industry is moderately consolidated, with dominant players using tactics like innovation, strategic alliances, and geographic growth to consolidate their positions. Major players are competing by investing in cutting-edge genomic technologies, collaborating to improve diagnostic capabilities, and growing their presence in emerging economies.
Key Developments in 2024
Rising cancer rates and demand for non-invasive diagnostics are fueling rapid adoption.
Advanced genomic tools and liquid biopsy tech have boosted test accuracy and clinical use.
Bladder cancer surveillance leads due to recurring need and clinical utility.
Mail-order and at-home collection are surging due to convenience and telehealth alignment.
Genomic urine testing is set to become routine in cancer care with global uptake and expanded panels.
Primary Detection, Bladder Cancer Surveillance
Hospital Pharmacies, Mail Order Pharmacies and Speciality Pharmacies
North America, Latin America, Europe, East Asia, South Asia, Oceania and the Middle East and Africa
Genomic Urine Testing Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
